Literature DB >> 8098932

Neuroleptic medications inhibit complex I of the electron transport chain.

C Burkhardt1, J P Kelly, Y H Lim, C M Filley, W D Parker.   

Abstract

Neuroleptic medications are prescribed to millions of patients, but their use is limited by potentially irreversible extrapyramidal side effects. Haloperidol shows striking structural similarities to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which produces parkinsonism apparently through inhibition of NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial electron transport chain. We now report that haloperidol, chlorpromazine, and thiothixene inhibit complex I in vitro in rat brain mitochondria. Clozapine, an atypical antipsychotic reported to have little or no extrapyramidal toxicity, also inhibits complex I, but at a significantly higher concentration. Neuroleptic treated patients have significant depression of platelet complex I activity similar to that seen in idiopathic Parkinson's disease. Complex I inhibition may be associated with the extrapyramidal side effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098932     DOI: 10.1002/ana.410330516

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  52 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 2.  Oxidative mechanisms and tardive dyskinesia.

Authors:  James B Lohr; Ronald Kuczenski; Alexander B Niculescu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  The genetic basis of Parkinson's disease.

Authors:  T Foltynie; S Sawcer; C Brayne; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

Review 4.  Functionalized nanosystems for targeted mitochondrial delivery.

Authors:  Shelley A Durazo; Uday B Kompella
Journal:  Mitochondrion       Date:  2011-11-23       Impact factor: 4.160

5.  Gene networks and haloperidol-induced catalepsy.

Authors:  O D Iancu; P Darakjian; B Malmanger; N A R Walter; S McWeeney; R Hitzemann
Journal:  Genes Brain Behav       Date:  2011-11-11       Impact factor: 3.449

6.  Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Lu Rongzhu; Shrinivas K Kulkarni
Journal:  Neurotox Res       Date:  2010-11-13       Impact factor: 3.911

Review 7.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 8.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

9.  The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets.

Authors:  N Sasaki; M Iwase; Y Uchizono; U Nakamura; H Imoto; S Abe; M Iida
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

10.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.